IP Library › Patent Application 16245382
Patent Application
App. No. 16/245,382

SEQUENCING-DIRECTED SELECTION OF TUMOR THERANOSTICS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/245,382
Abstract

The present disclosure relates to therapies for the treatment of tumor, autoimmune diseases, or other diseases. In some embodiments, the present disclosure can relate to subject-specific selection of humanized antibodies targeting clonal lineage specific marker proteins.

Claims (4)

1 . A humanized construct comprising:

a. a first domain having an affinity for a clonal lineage specific marker protein (CLSMP); and

b. a second domain having an affinity for an effector antigen selected from the group consisting of CD3, CD28, CTLA4, PD-1, IL-2R, and Fc receptor.

2 .- 127 . (canceled)

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2020
From: AFFIGEN, LLC
To: COLLINS, MIKE
Reel/Frame 053461/0054 →